NEW YORK – Personalis said Thursday in a filing with the US Securities and Exchange Commission that it and rival liquid biopsy firm Foresight Diagnostics have agreed to settle pending litigation and inter partes review proceedings related to blood-based cancer diagnostic testing patents.
Under the agreement, Foresight and Personalis will dismiss the pending claims of infringement and related defenses and counterclaims against one another, with Personalis granting Foresight a nonexclusive, worldwide license to certain patents related to whole-genome sequencing-based minimal residual disease testing.
In its SEC filing, Personalis said that Foresight has agreed to pay a "low-single digit tiered royalty" on net sales of such tests.